Boehringer Ingelheim Chairman von Baumbach Highlights Strong H1 2024 Performance and Pipeline Milestones

Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, ...

July 18, 2024 | Thursday | News
Paul Limburg Highlights Commitment to Reducing Screening Disparities Through the FOCUS Program's Support of 28 Organizations Nationwide

  Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced  that it awarded a total of $1.5 million to 28 organiza...

July 18, 2024 | Thursday | News
GC Cell and Checkpoint Therapeutics Announce Collaboration to Explore Synergistic Cancer Therapies

Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell thera...

July 16, 2024 | Tuesday | News
Taiwan's Senhwa Biosciences Submits IND to US FDA for Phase I/II Study of Silmitasertib in Pediatric Cancer Treatment

  Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with c...

July 12, 2024 | Friday | News
Thermo Fisher Scientific to Advance Myeloid Cancer Research with Next-Generation Sequencing Technology

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is proud to announce its partnership with the National Cancer Institute (...

July 12, 2024 | Friday | News
Daiichi Sankyo Expands European Presence with New Oncology Affiliate in Greece

Daiichi Sankyo  announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company&r...

July 10, 2024 | Wednesday | News
Epsilogen Receives MHRA Approval for Phase Ib Trial of MOv18 IgE in Treating Platinum-Resistant Ovarian Cancer

Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application f...

July 09, 2024 | Tuesday | News
Eli Lilly to Acquire Morphic Holding for $3.2 Billion, Expanding Gastroenterology Portfolio

Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF)  announced a definitive agreement for Lilly to acquire Mor...

July 09, 2024 | Tuesday | News
Merck and and Orion Announce Exercise of Option for Exclusive Global License of Opevesostat, Advancing Prostate Cancer Treatment

Merck  known as MSD outside of the United States and Canada, and Orion Corporation announced that notice has been provided of the mutual exercise of...

July 02, 2024 | Tuesday | News
SCG Cell Therapy Receives FDA Approval for IND to Initiate HPV TCR T Cell Therapy Trials in Singapore

SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today anno...

July 01, 2024 | Monday | News
BioNTech and DualityBio's ADC Candidate BNT324/DB-1311 Gains FDA Fast-Track Status for Prostate Cancer

The status is based on preclinical data and data from an ongoing phase 1/2 study for BNT324/DB-1311; preliminary phase 1/2 clinical data showed anti-tu...

June 25, 2024 | Tuesday | News
Mika Health, AstraZeneca, and Daiichi Sankyo Launch "UNITE" Initiative to Enhance Breast Cancer Treatment Experience

Mika Health, a global digital therapeutics developer specializing in meeting the needs of cancer patients, in collaboration with AstraZenecaand Daiichi S...

June 19, 2024 | Wednesday | News
Macomics and IOR Collaborate to Advance Prostate Cancer Research with Novel Macrophage-Targeted Therapies

Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloi...

June 19, 2024 | Wednesday | News
Junshi Biosciences' Toripalimab Approved in China for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...

June 18, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in